Date: 2013-07-31
Type of information: Grant
Company: Videregen Cell (UK)Therapy Catapult (UK) NHS Blood and Transplant (UK) Royal Free London NHS Foundation Trust (UK) University College London (UK)
Investors: Technology Strategy Board (UK)
Amount: £2million (€2.3 million)
Funding type: award
Planned used: The consortium will use the funds to progress a promising clinical prototype through a rigorous development process and early clinical trials for the treatment of severe structural airway disease (SSAD). SSAD is associated with significant airway obstruction leading to high levels of morbidity and a 50% mortality rate if not treated successfully. Current treatment involves surgery which has a high incidence of failure and lack of efficacy. In contrast, this tracheal replacement approach, which involves repopulating an acellular trachea \'scaffold\' with the patient\'s own stem cells and epithelial cells, has the potential to be a one-off treatment without the need for a lifetime of anti-rejection drugs thereafter.
Others:
Therapeutic area: Regenerative medicine - Respiratory diseases